Site icon OncologyTube

AIM2CERV: A Phase 3 Trial for Cervical Cancer

Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center gives an overview of his presentation, AIM2CERV: Global Phase 3 Trial of Advaxis Axalimogene Filolisbac for Cervical Cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Exit mobile version